In the November issue of PME behaviour change looms large, firstly with a look at a new Sanofi board that’s been tasked with improving outcomes and generating business success.
Led by global head of patient solutions Dr Anne Beal, the behavioural science advisory board’s other members bring expertise in areas such as social learning, patient activation and economics.
As Dr Beal told us: “We recognised there was a gap between how medicines performed under ideal conditions in clinical trials and in the real world, so the question became what can we do to improve the performance of our products in the real world?”
We also look at the global focus in healthcare communications to secure behavioural change and how it’s driving a step change in industry efforts. Sustainable behaviour change, our cover feature concludes, should be a ‘group dance’ that never ends.
Among this month’s other highlights is an exclusive report on a recent high-level industry debate, QuintilesIMS’ The Future of Pharma and Life Sciences in the UK, which heard from senior figures from NICE, industry and the NHS.
Brexit and conducting real-world studies featured prominently at the London meeting, which brought a measure of clarity to the situation in the UK as the country prepares to leave the European Union.
Register here to receive email notification of future digital editions of PME or contact the subscriptions department to enquire about receiving a print copy of the magazine. More PMLiVE digital editions can be found here.
PME is also available to download as an app for iPhone and iPad
